🇺🇸 FDA
Patent

US 10975150

Anti-CD74 antibodies, compositions comprising anti-CD74 antibodies and methods of using anti-CD74 antibodies

granted A61PA61P35/00

Quick answer

US patent 10975150 (Anti-CD74 antibodies, compositions comprising anti-CD74 antibodies and methods of using anti-CD74 antibodies) held by Sutro Biopharma, Inc. expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sutro Biopharma, Inc.
Grant date
Tue Apr 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
29
CPC classes
A61P, A61P35/00